http://lookfordiagnosis.com
English
Spanish
Italian
Portuguese
French
Swedish


Private Partnerships for Public Benefit
Nobel Prize laureate Stanley Prusiner (left), director of the UCSF Institute of Neurodegenerative Diseases, recently launched a partnership with pharmaceutical company Daiichi Sankyo that will accelerate his research into prion diseases. He credits the ...
UCSF News Services - Thu, 17 Apr 2014 08:45

OncoBriefs: Chemo for Bladder Cancer, Myeloma Care
"By contrast with some of the other hematological malignancies, myeloma has many potential complications at diagnosis and relapse, including bone disease and fracture, severe and complex pain, and renal failure," the authors noted. "These problems ...
MedPage Today - Thu, 17 Apr 2014 13:03

Less Cognitive Loss With Reduced- Intensity Transplant
The most common underlying diseases were acute leukemia and myelodysplastic syndromes, found in 69% of patients. Slightly less than half received full-intensity conditioning. Almost 60% received a transplant from an unrelated donor. As part of a study ...
Clinical Oncology News - Thu, 17 Apr 2014 08:45

Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with ...
DCR-MYC, Dicerna's first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR ...
The Herald | HeraldOnline.com (press release) - Wed, 16 Apr 2014 13:15

Investor's Watch List - Geron Corporation (NASDAQ:GERN), IsoRay, Inc (ISR ...
Las Vegas, NV – April 19, 2013 — (Tech Sonian) –Geron Corporation (NASDAQ:GERN) a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is ...
Techsonian (press release) - Sat, 19 Apr 2014 05:00

Tolero Pharmaceuticals Announces Presentation at AACR Describing a ...
SALT LAKE CITY--(BUSINESS WIRE)--Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that a poster related to its development program alvocidib, a potent cyclin-dependent ...
Business Wire (press release) - Mon, 07 Apr 2014 05:22



Does Bee Sting Therapy Help Ease MS Symptoms?
However, they point out that no major studies on BVT have been done, and that it is estimated that only about 50 U.S. physicians use Apitherapy to treat MS or other diseases, observing that the evidence of BVT helping MS patients, while encouraging ...
BioNews Texas - Tue, 15 Apr 2014 09:59

True North Therapeutics Publishes Study in Blood Demonstrating Ex Vivo ...
By precisely targeting the Classical Complement pathway, TNT009 offers a novel approach for treating Complement-mediated diseases with significant unmet medical needs in the hematologic, renal, and neurological therapeutic areas. With a unique ...
Business Wire (press release) - Mon, 14 Apr 2014 06:07


1  2  3  4  5  6  7  8    ->

Last update: April 2009
Statistics